Compare Inovio Pharmaceuticals Inc (INO) vs Viatris Inc (VTRS) Price & Performance

INO trades at $1.24, up 7.83% today, with a neutral technical signal despite bullish moving averages. The company shows consistent quarterly earnings beats but faces severe financial strain with a -130,000% net income margin and negative cash flow. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus at Buy (58.83%) and a $2.75 price target.

Outlook hinges on FDA approval driving revenue; without it, cash burn and negative profitability pose significant downside. High valuation multiples (P/S 961.51) reflect speculative growth expectations. Risks include regulatory delays and dependence on single product success. Institutional sentiment is cautiously optimistic pending clinical milestones.

Viatris (VTRS) trades at $16.95, down 0.41% with a bullish technical outlook despite recent negative net income margins. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations by 15%. Recent FDA approvals for women's health products and strong cash flow generation support operational stability. Analyst consensus price target stands at $20.50, representing 21% upside potential from current levels.

While facing profitability challenges with negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers value appeal with reasonable P/S and P/B ratios, but investors must weigh debt levels against recent pipeline progress and market share gains in key regions.